Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study
- Author(s)
- Fowler, NH; Dickinson, M; Ghosh, M; Chen, AI; Andreadis, C; Tiwari, R; Masood, A; Ramos, R; Jousseaume, E; Thieblemont, C; Dreyling, M; Schuster, SJ;
- Details
- Publication Year 2023-01,Volume 29,Issue #1,Page 60.e1-60.e4
- Journal Title
- Transplantation and Cellular Therapy
- Publication Type
- Research article
- Abstract
- Follicular lymphoma (FL) is generally considered an indolent disease, although patients with relapsing FL experience progressively shorter durations of response to second or later lines of therapy. The ongoing ELARA trial in adult patients with relapsed/refractory (r/r) FL treated with tisagenlecleucel demonstrated an overall response rate of 86.2% and a complete response rate of 69.1%, with no treatment-related deaths. Tisagenlecleucel was administered in the outpatient setting in 18% of patients in ELARA; however, there is limited knowledge concerning the impact of inpatient versus outpatient tisagenlecleucel administration on healthcare resource utilization (HCRU) among patients with r/r FL. Here, we present the first HCRU analysis among patients with r/r FL who received tisagenlecleucel in the Phase II, single-arm, multicenter ELARA trial. HCRU was characterized using hospitalization data from day 1 to month 2 after tisagenlecleucel infusion. Information on length of stay, facility use, and discharge was assessed in patients who received tisagenlecleucel in the outpatient or inpatient setting. All costs were inflated to 2020 US dollars. As of August 3, 2021 (20-month median follow-up), 17/97 (18%) r/r FL patients were infused in an outpatient setting. Patients infused in the outpatient setting generally had favorable Eastern Cooperative Oncology Group performance status and Follicular Lymphoma International Prognostic Index scores, and less bulky disease at baseline. However, the outpatients had higher proportions of patients with grade 3A FL, primary refractory disease, and >5 lines of prior therapy compared with inpatients. Forty-one percent of patients treated in the outpatient setting did not require hospitalization within 30 days after infusion, and outpatients who did require hospitalization had a shorter average length of stay compared with inpatients (5 versus 13 days). No outpatients required intensive care unit (ICU) admission, whereas 9% of inpatients were admitted to the ICU. The mean postinfusion hospitalization costs were $7477 and $40,054 in the outpatient and inpatient settings, respectively. Efficacy between both groups was similar. Tisagenlecleucel can be safely administered to some patients in the outpatient setting, which may reduce HCRU for patients with r/r FL.
- Publisher
- Elsevier
- Keywords
- Adult; Humans; *Lymphoma, Follicular/therapy; *Receptors, Chimeric Antigen; Neoplasm Recurrence, Local; Hospitalization; Patient Acceptance of Health Care; Cell- and Tissue-Based Therapy; CAR-T cell therapy; Elara; Follicular lymphoma; Outpatient; Tisagenlecleucel
- Department(s)
- Clinical Haematology
- PubMed ID
- 36182104
- Publisher's Version
- https://doi.org/10.1016/j.jtct.2022.09.022
- Open Access at Publisher's Site
10.1016/j.jtct.2022.09.022- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-04-06 06:53:47
Last Modified: 2024-07-10 06:34:21